美国食品药品监督管理局批准新型抗流感病毒药物 - Suppr

FDA Approves New Antiviral for Influenza.

作者信息

Aschenbrenner Diane S

机构信息

Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch:

出版信息

Am J Nurs. 2019 Feb;119(2):21. doi: 10.1097/01.NAJ.0000553202.36589.e2.

DOI:10.1097/01.NAJ.0000553202.36589.e2

PMID:30681474

Abstract

摘要

相似文献

FDA Approves New Antiviral for Influenza.

Am J Nurs. 2019 Feb;119(2):21. doi: 10.1097/01.NAJ.0000553202.36589.e2.

Baloxavir Marboxil (Xofluza) for Influenza.

Am Fam Physician. 2019 Dec 15;100(12):776-777.

Sixty seconds on . . . baloxavir.

BMJ. 2018 Oct 26;363:k4531. doi: 10.1136/bmj.k4531.

Effectiveness of baloxavir marboxil against influenza in children.

Pediatr Int. 2019 Jun;61(6):616-618. doi: 10.1111/ped.13855. Epub 2019 Jun 13.

Baloxavir: First Global Approval.

Drugs. 2018 Apr;78(6):693-697. doi: 10.1007/s40265-018-0899-1.

Introducing the new anti-influenza drug, baloxavir marboxil.

Respir Investig. 2020 Jan;58(1):1-3. doi: 10.1016/j.resinv.2019.10.005. Epub 2019 Nov 29.

New Drugs 2019, part 3.

Nursing. 2019 Aug;49(8):24-32. doi: 10.1097/01.NURSE.0000569740.20055.9e.

Baloxavir heralds a new era in influenza virus biology.

Respir Investig. 2019 Jan;57(1):1-2. doi: 10.1016/j.resinv.2018.10.002. Epub 2018 Nov 3.

Baloxavir marboxil: a novel cap-dependent endonuclease (CEN) inhibitor for the treatment of acute uncomplicated influenza.

Drugs Today (Barc). 2019 Jun;55(6):359-366. doi: 10.1358/dot.2019.55.6.2999889.

[Baloxavir marboxil: a potent cap-dependent endonuclease inhibitor of influenza viruses].

Rev Esp Quimioter. 2019 Feb;32(1):1-5. Epub 2019 Jan 23.

引用本文的文献

A review of policies and coverage of seasonal influenza vaccination programs in the WHO Eastern Mediterranean Region.

Influenza Other Respir Viruses. 2023 Mar 21;17(3):e13126. doi: 10.1111/irv.13126. eCollection 2023 Mar.

Next-generation direct-acting influenza therapeutics.

Transl Res. 2020 Jun;220:33-42. doi: 10.1016/j.trsl.2020.01.005. Epub 2020 Feb 4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

FDA Approves New Antiviral for Influenza.

Am J Nurs. 2019 Feb;119(2):21. doi: 10.1097/01.NAJ.0000553202.36589.e2.

Baloxavir Marboxil (Xofluza) for Influenza.

Am Fam Physician. 2019 Dec 15;100(12):776-777.

Sixty seconds on . . . baloxavir.

BMJ. 2018 Oct 26;363:k4531. doi: 10.1136/bmj.k4531.

Effectiveness of baloxavir marboxil against influenza in children.

Pediatr Int. 2019 Jun;61(6):616-618. doi: 10.1111/ped.13855. Epub 2019 Jun 13.

Baloxavir: First Global Approval.

Drugs. 2018 Apr;78(6):693-697. doi: 10.1007/s40265-018-0899-1.

Introducing the new anti-influenza drug, baloxavir marboxil.

Respir Investig. 2020 Jan;58(1):1-3. doi: 10.1016/j.resinv.2019.10.005. Epub 2019 Nov 29.

New Drugs 2019, part 3.

Nursing. 2019 Aug;49(8):24-32. doi: 10.1097/01.NURSE.0000569740.20055.9e.

Baloxavir heralds a new era in influenza virus biology.

Respir Investig. 2019 Jan;57(1):1-2. doi: 10.1016/j.resinv.2018.10.002. Epub 2018 Nov 3.

Baloxavir marboxil: a novel cap-dependent endonuclease (CEN) inhibitor for the treatment of acute uncomplicated influenza.

Drugs Today (Barc). 2019 Jun;55(6):359-366. doi: 10.1358/dot.2019.55.6.2999889.

[Baloxavir marboxil: a potent cap-dependent endonuclease inhibitor of influenza viruses].

Rev Esp Quimioter. 2019 Feb;32(1):1-5. Epub 2019 Jan 23.

引用本文的文献

A review of policies and coverage of seasonal influenza vaccination programs in the WHO Eastern Mediterranean Region.

Influenza Other Respir Viruses. 2023 Mar 21;17(3):e13126. doi: 10.1111/irv.13126. eCollection 2023 Mar.

Next-generation direct-acting influenza therapeutics.

Transl Res. 2020 Jun;220:33-42. doi: 10.1016/j.trsl.2020.01.005. Epub 2020 Feb 4.

FDA Approves New Antiviral for Influenza.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

FDA Approves New Antiviral for Influenza.

作者信息

机构信息

出版信息

相似文献

引用本文的文献